Antiretroviral therapy
Antiretroviral therapy (art) is the standard treatment for human immunodeficiency virus infection: combinations of drugs that block distinct stages of the viral life cycle.
Antiretroviral therapy (art) is the standard treatment for human immunodeficiency virus infection: combinations of drugs that block distinct stages of the viral life cycle. Combination provides greater antiviral potency and a higher barrier to resistance — HIV's reverse transcriptase is error-prone and its replication rate enormous, so any single agent selects a resistant variant within weeks, while simultaneous blockade at several steps requires more mutations than the virus can readily accumulate. The classes are nucleoside and nucleotide reverse transcriptase inhibitors, non-nucleoside reverse transcriptase inhibitors, protease inhibitors, and integrase strand transfer inhibitors, the last — exemplified by dolutegravir — now anchoring most regimens worldwide for their potency, tolerability and high barrier to resistance. Suppressing plasma HIV RNA below detection prevents progressive immunodeficiency, protects against opportunistic infection, and blocks sexual transmission entirely, the finding behind "undetectable equals untransmittable". The same drugs given to uninfected people at risk work as pre-exposure prophylaxis.
art has turned a uniformly fatal disease into a chronic condition with near-normal life expectancy when suppression is maintained — the qualification that matters, since benefit depends on sustained adherence, and interruption brings both viral rebound and the risk of resistance. Long-acting injectable regimens given every one or two months address exactly that constraint.
What art does not do is cure. Provirus integrates into the host genome of long-lived CD4+ T cells, including CD4+ effector memory T cells, within days of infection, and this reservoir is transcriptionally silent, invisible to immune surveillance and untouched by drugs that act only on replication — so rebound follows interruption within weeks. Chronic immune activation persists despite suppression, driven partly by residual antigen, microbial translocation and coinfection, raising inflammatory markers such as C-reactive protein (CRP) and dysregulating the Mechanistic target of rapamycin (mTOR) pathway, and linking treated HIV to accelerated aging, cardiometabolic disease and neurological injury. These residual pathologies, along with weight gain seen with integrase inhibitors, define the frontier of current research and motivate work toward functional cure and art-free remission.
Where the papers sit
11 papers from the last 6 months study antiretroviral therapy directly · updated from PubMed 16 Nov 2026
Study type 3 clinical trials · 3 observational · 5 human data
Themes 3 themes · 1 paradigm shift
-
HIV Care Retention and Adherence
HIV programs are shifting toward sustained retention through multi-month dispensing, adherence counseling, and closer attention to barriers after ART initiation. Loss to follow-up remains concentrated around pregnancy, health-system access, and other social pressures. Adherence is also being tracked during bedaquiline treatment for multidrug-resistant tuberculosis. Pegylated interferon-α studies extend the agenda toward HIV reservoir clearance, but this remains investigational rather than established care.
5 papers · 45.5%
-
HIV Immune Recovery
HIV treatment outcomes are linked to CD4+ T-cell dysfunction, cellular exhaustion, and persistent viral reservoirs. Cerebrospinal-fluid HIV escape appears as a complication during cryptococcal meningitis, while nonresponders show disturbed CD4+ T-cell profiles. Mathematical models add cure-rate and transmission perspectives rather than a tested clinical intervention. The cluster shares an HIV persistence and immune-recovery focus but shows no single research direction.
3 papers · 27.3%
-
Digital HIV Adherence Support
Digital support is moving toward culturally tailored, just-in-time interventions for people living with HIV. Geofencing and iOS or Android apps are being adapted for adolescents, young adults, and people affected by violence. Alcohol use and tobacco smoking recur as behavioral barriers to antiretroviral adherence, motivating more personalized support. Engagement and real-world effectiveness remain open questions.
3 papers · 27.3%
Systemic viral suppression on antiretroviral therapy does not ensure immune reconstitution or viral control in other compartments
The study of people with HIV who were immunological non-responders despite treatment 42853340Oct and the case of cryptococcal meningitis with cerebrospinal-fluid HIV escape during continuous treatment 42749340Sep both challenge the assumption that antiretroviral therapy’s systemic viral suppression reliably produces complete biological control. The first found persistent CD4+ T-cell disturbance and elevated exhaustion-related genes despite viral suppression, while the second found detectable cerebrospinal-fluid HIV RNA despite suppressed serum virus and stable CD4-cell counts. Together, they shift the account from ART as uniformly controlling HIV and restoring immunity to ART as control that may fail to produce immune recovery or may leave compartment-specific viral activity requiring additional investigation and, in the CNS case, treatment intensification.
Papers
The 11 papers from the last 6 months that study antiretroviral therapy directly, newest first, by theme and by study type. Study types come from PubMed publication types and MeSH headings.
By theme
HIV Care Retention and Adherence (5)
- Temporal proximity to counseling is associated with longitudinal bedaquiline and antiretroviral therapy adherence in multidrug-resistant tuberculosis and HIV treatment. PloS one · 5 Oct 2026 PMID 42832504
- What went wrong? A qualitative exploration of the determinants of poor adherence to antiretroviral therapy and retention in care among pregnant and postpartum women in the Uganda WiseMama trial. Global public health · 24 Sept 2026 PMID 42779011
- Incidence and predictors of loss to follow-up after ART initiation at public health facilities in Sierra Leone (2020-2024): a retrospective cohort study. BMJ open · 24 Jul 2026 PMID 42498473
- Effectiveness of pegylated interferon-α combined with antiretroviral therapy on HIV reservoir clearance in acute HIV infection: study protocol for a randomised controlled trial at a tertiary infectious disease hospital in Beijing, China. BMJ open · 2 Jul 2026 PMID 42392622
- HIV Care Retention and Cost Analysis in Multi-Month ART Dispensing: A Randomized Controlled Trial in China. Journal of the International AIDS Society · 24 Jun 2026 PMID 42339560
HIV Immune Recovery (3)
- Upregulation of cellular exhaustion-related genes and CD4 + T cell disturbances in immunological non-responders on antiretroviral therapy. Immunologic research · 9 Oct 2026 PMID 42853340
- Cryptococcal meningitis with cerebrospinal fluid human immunodeficiency virus escape presenting as transient diplopia and areflexia. BMJ case reports · 16 Sept 2026 PMID 42749340
- A modified HIV model with Beddington-DeAngelis incidence and cure rate. Scientific reports · 26 May 2026 PMID 42191796
Digital HIV Adherence Support (3)
- A Geospatially Customizable Culturally Tailored Just-in-Time Adaptive Intervention for Violence-Affected People Living With HIV: Mixed Methods Acceptability, Feasibility, and User Experience Study. JMIR human factors · 26 Jun 2026 PMID 42360924
- Alcohol consumption and tobacco smoking associated with decreased antiretroviral therapy adherence among people living with HIV in Zambia: Evidence from a 2023 national NCDs/ HIV survey. PloS one · 12 Jun 2026 PMID 42284276
- Adapting a medication adherence app for adolescents and young adults in Makurdi, Benue State: The Lu Dedoo Project. PloS one · 29 May 2026 PMID 42213746
By study type
Clinical trials (3)
- Temporal proximity to counseling is associated with longitudinal bedaquiline and antiretroviral therapy adherence in multidrug-resistant tuberculosis and HIV treatment. PloS one · 5 Oct 2026 PMID 42832504
- Effectiveness of pegylated interferon-α combined with antiretroviral therapy on HIV reservoir clearance in acute HIV infection: study protocol for a randomised controlled trial at a tertiary infectious disease hospital in Beijing, China. BMJ open · 2 Jul 2026 PMID 42392622
- HIV Care Retention and Cost Analysis in Multi-Month ART Dispensing: A Randomized Controlled Trial in China. Journal of the International AIDS Society · 24 Jun 2026 PMID 42339560
Observational studies and case reports (3)
- Cryptococcal meningitis with cerebrospinal fluid human immunodeficiency virus escape presenting as transient diplopia and areflexia. BMJ case reports · 16 Sept 2026 PMID 42749340
- Incidence and predictors of loss to follow-up after ART initiation at public health facilities in Sierra Leone (2020-2024): a retrospective cohort study. BMJ open · 24 Jul 2026 PMID 42498473
- Alcohol consumption and tobacco smoking associated with decreased antiretroviral therapy adherence among people living with HIV in Zambia: Evidence from a 2023 national NCDs/ HIV survey. PloS one · 12 Jun 2026 PMID 42284276
Human data, design not indexed (5)
- Upregulation of cellular exhaustion-related genes and CD4 + T cell disturbances in immunological non-responders on antiretroviral therapy. Immunologic research · 9 Oct 2026 PMID 42853340
- What went wrong? A qualitative exploration of the determinants of poor adherence to antiretroviral therapy and retention in care among pregnant and postpartum women in the Uganda WiseMama trial. Global public health · 24 Sept 2026 PMID 42779011
- A Geospatially Customizable Culturally Tailored Just-in-Time Adaptive Intervention for Violence-Affected People Living With HIV: Mixed Methods Acceptability, Feasibility, and User Experience Study. JMIR human factors · 26 Jun 2026 PMID 42360924
- Adapting a medication adherence app for adolescents and young adults in Makurdi, Benue State: The Lu Dedoo Project. PloS one · 29 May 2026 PMID 42213746
- A modified HIV model with Beddington-DeAngelis incidence and cure rate. Scientific reports · 26 May 2026 PMID 42191796
Written from 11 PubMed abstracts, each one listed by PMID above. Published: 2026-06-16. Last written: 2026-09-26 by GPT. Corrections: 2026-09-26 by GPT. Drafted by language models from published abstracts; not medical advice.